Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization
AssigneeGene Signal International SA
InventorSalman AL MAHMOOD
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition including as active agent, an antisens oligonucleotide having the sequence SEQ ID NO: 1 in a concentration from about 0.40 mg/ml to about 2 mg/ml and the use thereof for preventing, stabilizing and/or inhibiting blood and lymph vascularization.
Claims17
A pharmaceutical composition comprising as active agent, an antisens oligonucleotide having the sequence SEQ ID NO:
- 1 or any function-conservative sequence comprising from 9 to 30 nucleotides that has 75% of identity compared to SEQ ID NO:
- 1, wherein said antisens oligonucleotide is in a concentration from about 0.40 mg/ml to about 2 mg/ml.
A method for treating corneal graft rejection, comprising the administration the a subject in need thereof of a composition comprising as active agent, an antisens oligonucleotide having the sequence SEQ ID NO:
- 1 or any function-conservative sequence comprising from 9 to 30 nucleotides that has 75% of identity compared to SEQ ID NO:
- 1, wherein said antisens oligonucleotide is in a concentration from about 0.40 mg/ml to about 2 mg/ml.
A method for reducing the risk of immune rejection after corneal grafting, comprising the administration the a subject in need thereof of a composition comprising as active agent, an antisens oligonucleotide having the sequence SEQ ID NO:
- 1 or any function-conservative sequence comprising from 9 to 30 nucleotides that has 75% of identity compared to SEQ ID NO:
- 1, wherein said antisens oligonucleotide is in a concentration from about 0.40 mg/ml to about 2 mg/ml.
A method for treating glaucoma, comprising the administration the a subject in need thereof of a composition comprising as active agent, an antisens oligonucleotide having the sequence SEQ ID NO:
- 1 or any function-conservative sequence comprising from 9 to 30 nucleotides that has 75% of identity compared to SEQ ID NO:
- 1, wherein said antisens oligonucleotide is in a concentration from about 0.40 mg/ml to about 2 mg/ml.
A method for treating retinopathy comprising the administration the a subject in need thereof of a composition comprising as active agent, an antisens oligonucleotide having the sequence SEQ ID NO:
- 1 or any function-conservative sequence comprising from 9 to 30 nucleotides that has 75% of identity compared to SEQ ID NO:
- 1, wherein said antisens oligonucleotide is in a concentration from about 0.40 mg/ml to about 2 mg/ml.
A method for treating age related macular degeneration, comprising the administration the a subject in need thereof of a composition comprising as active agent, an antisens oligonucleotide having the sequence SEQ ID NO:
- 1 or any function-conservative sequence comprising from 9 to 30 nucleotides that has 75% of identity compared to SEQ ID NO:
- 1, wherein said antisens oligonucleotide is in a concentration from about 0.40 mg/ml to about 2 mg/ml.
Dependencies are inferred from the claim text.